Results 61 to 70 of about 10,157,624 (223)

Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression

open access: yesArthritis &Rheumatology, EarlyView.
Objective Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom ...
Sacha E. Silva‐Saffar   +6 more
wiley   +1 more source

HIV/AIDS Associated Lymphoma: Review

open access: yesBlood and Lymphatic Cancer: Targets and Therapy, 2022
Ayenew Berhan,1 Biruk Bayleyegn,2 Zegeye Getaneh2 1Department of Medical Laboratory Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 2Department of Hematology and Immunohematology, School of Biomedical and Laboratory ...
Berhan A, Bayleyegn B, Getaneh Z
doaj  

Guillain-Barré Syndrome Heralding the Diagnosis of Hodgkin Lymphoma: A Case Report

open access: yesCase Reports in Neurology, 2020
Lymphoma is a prevalent type of lymphoid tissue malignancy that is seldom associated with Guillain-Barré syndrome (GBS). In the majority of instances, both Hodgkin’s and non-Hodgkin’s lymphoma are not proceeded by GBS.
Alawi Aqel Al-Attas   +3 more
doaj   +1 more source

Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma [PDF]

open access: yes, 2004
Historically localised aggressive non-Hodgkin's lymphoma (NHL) has been treated with involved field radiotherapy (RT), chemotherapy, or a combination of both modalities. The current weight of evidence supports a preference for combined modality treatment
P Hoskin   +14 more
core   +1 more source

Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg   +2 more
wiley   +1 more source

GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers [PDF]

open access: yes, 2012
Background: Increased glycolytic activity is a hallmark of cancer, allowing staging and restaging with 18F-fluorodeoxyglucose-positron-emission-tomography (PET).
Pier Luigi Zinzani   +19 more
core   +2 more sources

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic   +7 more
wiley   +1 more source

Single‐cell RNA sequencing of peripheral blood defines two immunological subtypes of Sjögren's disease distinguished by anti‐SSA antibodies and aberrant B cell populations

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski   +15 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy